(This version of the June 22 story corrects paragraph 3 to say Weiss was a nominee and had not previously served on Natus’ board)
(Reuters) - Natus Medical Inc said on Friday its stockholders had elected hedge fund Voce Capital Management’s nominees to the company’s board, ending a months long proxy fight.
The medical device maker also said the preliminary count of votes showed that its stockholders had voted to reject Voce’s proposal to remove the company’s Chairman, Robert Gunst.
Voce’s nominees, Lisa Wipperman Heine and Joshua Levine, will join Natus’ board instead of incumbent director Doris Engibous and Robert Weiss, who the company wanted to add.
The hedge fund said, based on a preliminary report, its nominees received nearly 70 percent of the shares voted in the election.
Voce, run by Daniel Plants, owns 2.2 percent of Natus and tensions have been rising since March, when Plants asked for a meeting with the company’s board chairman and independent directors.
Natus shares rose 3 percent in late afternoon trading.
Reporting by Uday Sampath in Bengaluru; Editing by Shailesh Kuber